

**INFORMATION DISCLOSURE STATEMENT
APPLICANT**

Attorney Docket Number	4239-67016-02
Application Number	10/532,374
Filing Date	April 21, 2005
First Named Inventor	Berzofsky
Art Unit	
Examiner Name	

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/SJH/		WIPO/PCT	WO 99/13912	March 25, 1999	HANNA <i>et al.</i>

EXAMINER
SIGNATURE:

/Sheela J. Huff/

DATE

CONSIDERED:

05/31/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/532374
JG12 Rec'd PCT/PTC 21 APR 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-67016-02
	Application Number	
	Filed	Herewith
	First Named Inventor	Berzofsky
	Art Unit	
	Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
/SJH/		5,772,998	30 June 1998	Dasch <i>et al.</i>
/SJH/		5,844,099	1 Dec 1998	Stahl <i>et al.</i>
/SJH/		6,046,165	4 April 2000	Laughon <i>et al.</i>
/SJH/		6,090,383	18 July 2000	Dasch <i>et al.</i>
/SJH/		6,120,763	19 Sept 2000	Fakhrai <i>et al.</i>
/SJH/		6,383,733	7 May 2002	Beug <i>et al.</i>
/SJH/		6,410,043	25 June 2002	Steiner <i>et al.</i>
/SJH/		6,419,928	16 July 2002	Dasch <i>et al.</i>
/SJH/		2003/0125251	3 July 2003	Wakefield <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/SJH/		WIPO/PCT	WO 97/49421	31 Dec 1997	Regents of the University of Minnesota
/SJH/		WIPO/PCT	WO 99/63975	16 Dec 1999	Biognostick Gesellschaft für Biomolekulare Diagnostik MBH

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
/SJH/		AHLERS <i>et al.</i> , "A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte / macrophage colony-stimulating factor and CD40L," <i>PNAS</i> 99(2):13020-13025, October 1, 2002

EXAMINER SIGNATURE: /Sheela J. Huff/	DATE CONSIDERED: 05/31/2007
--------------------------------------	-----------------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/532374

200512 Rec'd PCT/PT 21 APR 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67016-02
		Application Number	
		Filed	Herewith
		First Named Inventor	Berzofsky
		Art Unit	
		Examiner Name	
/SJH/		AKHURST <i>et al.</i> , "Genetic Events and the Role of TGF β in Epithelial Tumour Progression," <i>J. Pathol.</i> 187:82-90, 1999	
		AKHURST, "TGF-beta antagonists: why suppress a tumor suppressor?" <i>J. Clin. Invest.</i> 109:1533-1536, 2002	
		ARTEAGA <i>et al.</i> , "Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression," <i>J. Clin. Invest.</i> 92:2569-2576, 1993	
		AZUMA <i>et al.</i> , "Lack of Expression of Transforming Growth Factor- β Type II Receptor Associated with Malignant Progression in Human Salivary Gland Cell Clones," <i>Int. J. Cancer</i> 66:802-805, 1996	
		BLOBE <i>et al.</i> , "Role of Transforming Growth Factor β in Human Disease," <i>New Eng. J. Med.</i> 342:1350-1358, 2000	
		BOLLARD <i>et al.</i> , "Adapting a Transforming Growth Factor Beta-Related Tumor Protection Strategy to Enhance Antitumor Immunity," <i>Blood</i> 99(9):3179-3187, 2002	
		BORDER <i>et al.</i> , "Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease," <i>Nature</i> 360:361-364, 1992	
		BÖTTINGER <i>et al.</i> , "The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice," <i>PNAS USA</i> 93:5877-5882, 1996	
		BRISTOW <i>et al.</i> , "Altered Expression of Transforming Growth Factor-Beta Ligands and Receptors in Primary and Recurrent Ovarian Carcinoma," <i>Cancer</i> 85(3):658-668, 1999 (abstract only)	
		BURMESTER <i>et al.</i> , "Characterization of distinct functional domains of transforming growth factor β ," <i>Proc. Natl. Acad. Sci. USA</i> 90:8628-8632, 1993	
		CAVER <i>et al.</i> , "Intracellular Demonstration of Active TGF β 1 in B Cells and Plasma Cells of Autoimmune Mice," <i>J. Clin. Invest.</i> 11:2496-2506, 1996	
		DASCH <i>et al.</i> , "Monoclonal Antibodies Recognizing Transforming Growth Factor- β , Bioactivity Neutralization and Transforming Growth Factor β 2 Affinity Purification," <i>J. Immunol.</i> 142(5):1536-1541, 1989	
		EVANGELOU <i>et al.</i> , "Down-Regulation of Transforming Growth Factor β Receptors by Androgen in Ovarian Cancer Cells," <i>Cancer Res.</i> 60:929-935, 2000	
/SJH/		FRIEDMAN <i>et al.</i> , "High Levels of Transforming Growth Factor Beta 1 Correlate with Disease Progression in Human Colon Cancer," <i>Cancer Epidemiol. Biomarkers Prev.</i> 4(5):549-554, 1995 (abstract only)	
EXAMINER SIGNATURE:		/Sheela J. Huff/	DATE CONSIDERED: 05/31/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			

10/532374

AC/TMH:gte:dv 04/21/05 4239-67016-02 371404
PATENT

EXPRESS MAIL LABEL NO. EV510808507US

DATE OF DEPOSIT: April 21, 2005

3812 Rec'd PCT/PT 21 APR 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67016-02
		Application Number	
		Filed	Herewith
		First Named Inventor	Berzofsky
		Art Unit	
		Examiner Name	
/SJH/		GAZZANIGA <i>et al.</i> , "High Levels of Transforming Factor-Alpha (TGF-alpha) mRNA May Predict Local Relapses in Early Stage Urinary Bladder Cancer," <i>Eur. J. Cancer</i> 34(6):934-936, 1998 (abstract only)	
		GEORGE <i>et al.</i> , "In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: A potential new therapy for hepatic fibrosis," <i>PNAS</i> 96(22):12719-12724, 1999	
		GOLD, "The Role for Transforming Growth Factor- β (TGF- β) in Human Cancer," <i>Crit. Rev. Oncogen.</i> 10:303-360, 1999	
		GORELIK <i>et al.</i> , "Immune-Mediated Eradication of Tumors through the Blockade of Transforming Growth Factor- β Signaling in T Cells," <i>Nature Medicine</i> 7(10):1118-1122, 2001 (abstract only)	
		GOLGHER <i>et al.</i> , "Depletion of CD25 regulatory cells uncovers immune responses to shared murine tumor rejection antigens," <i>Eur. J. Immunol.</i> 32:3267-3275, 2002	
		GUO <i>et al.</i> , "Down-Regulation of Protein and mRNA Expression for Transforming Growth Factor- β (TGF- β 1) Type I and Type II Receptors in Human Prostate Cancer," <i>Int. J. Cancer</i> 71:573-579, 1997	
		ISAKA <i>et al.</i> , "Gene therapy by transforming growth factor- β receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis," <i>Kidney Internat.</i> 55:465-475, 1999	
		KANTO <i>et al.</i> , "Neutralization of Transforming Growth Factor Beta 1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction in Vitro," <i>J. Clin. Immunol.</i> 17(6):462-471, 1997 (abstract only)	
		KOMESLI <i>et al.</i> , "Chimeric extracellular domain of type II transforming growth factor (TGF)- β receptor fused to the Fc region of human immunoglobulin as a TGF- β antagonist," <i>Eur. J. Biochem.</i> 254:505-513, 1998	
		LEE <i>et al.</i> , "Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β_1 ," <i>J. Exp. Med.</i> 194(6):809-821, 2001	
		LEE <i>et al.</i> , "The Human Papilloma Virus E7 Oncoprotein Inhibits Transforming Growth Factor- β Signaling by Blocking Binding of the Smad Complex to Its Target Sequence," <i>J. Biological Chemistry</i> 277(41):38557-38564, October 11, 2002	
/SJH/		LUCAS <i>et al.</i> , "The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA." <i>J. Immunol.</i> 145(5):1415-1422, September 1, 1990 (abstract only)	

EXAMINER SIGNATURE:	/Sheela J. Huff/	DATE CONSIDERED:	05/31/2007
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

2 Rec'd PCT/PT 21 APR 2005

10/532374

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-67016-02
Application Number	
Filed	Herewith
First Named Inventor	Berzofsky
Art Unit	
Examiner Name	

/SJH/	MAO <i>et al.</i> , "Immunotherapy with Low-dose Inteerleukin-2 and Anti-transforming Growth Factor- β Antibody in a Murine Tumor Model," <i>Cancer Biotherapy</i> 9(4):317-327, 1994
	MASSAGUÉ <i>et al.</i> , "Controlling TGF-beta signaling," <i>Genes & Dev.</i> 14:627-644, 2000
	MASSAGUÉ <i>et al.</i> , "Transcriptional Control by the TGF- β /Smad Signaling System," <i>EMBO J.</i> 19(8):1745-1754, 2000
	MATSUI <i>et al.</i> , "A Model for CD8+ CTL Tumor Immunosurveillance and Regulation of Tumor Escape by CD4 T Cells Through an Effect on Quality of CTL," <i>J. Immunol.</i> 163:184-193, 1999.
	MCEARCHERN <i>et al.</i> , "Invasion and metastasis of a mammary tumor involves TGF-beta signaling," <i>Int. J. Cancer</i> 91:76-82, 2001
	MOUSTAKAS <i>et al.</i> , "Smad Regulation in TGF- β Signal Transduction," <i>J. Cell Sci.</i> 114:4359-4369, 2001
	MULÉ <i>et al.</i> , "Transforming Growth Factor-Beta Inhibits the in Vitro Generation of Lymphokine-Activated Killer Cells and Cytotoxic T Cells," <i>Cancer Immunol. Immunother.</i> 26:95-100, 1988
	MUROAKA <i>et al.</i> , "Blockade of TGF- β Inhibits Mammary Tumor Cell Viability, Migration, and Metastases," <i>J. Clin. Invest.</i> 109(12):1551-1559, 2002
	OFT <i>et al.</i> , "TGF β signaling is necessary for carcinoma cell invasiveness and metastasis," <i>Curr. Biol.</i> 8:1243-1252, 1998
	PARK <i>et al.</i> , "Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4(+) NKT regulatory cells and IL-13," <i>Int j. Cancer</i> 114:80-87, 2005
	QIAN <i>et al.</i> , "Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor β on endothelial cells," <i>Proc. Natl. Acad. Sci. USA</i> 89:6290-6294, 1992
	QIAN <i>et al.</i> , "Binding Affinity of Transforming Growth Factor- β for Its Type II Receptor Is Determined by the C-terminal Region of the Molecule," <i>J. Biol. Chem.</i> 271(48):30656-30662, 1996
	SEO <i>et al.</i> , "Depletion of IL-10- and TGF- β -Producing Regulatory $\gamma\delta$ T Cells by Administering a Daunomycin-Conjugated Specific Monoclonal Antibody in Early Tumor Lesions Augments the Activity of CTLs and NK Cells," <i>J. Immunol.</i> 163:242-249, 1999
/SJH/	SHARIAT <i>et al.</i> , "Preoperative Plasma Levels of Transforming Growth Factor Beta(1) (TGF-beta(1)) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy," <i>J. Clin. Oncol.</i> 19(11):2856-2864, 2001 (abstract only)

EXAMINER
SIGNATURE:

/Sheela J. Huff/

DATE

05/31/2007

CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/532374

AC/TMH:gte:dv 04/21/05 4239-67016-02 371404
PATENT

EXPRESS MAIL LABEL NO. EV510808507US

DATE OF DEPOSIT: April 21, 2005

2 Rec'd PC/PT 21 APR 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67016-02
		Application Number	
		Filed	Herewith
		First Named Inventor	Berzofsky
		Art Unit	
		Examiner Name	
/SJH/		SMITH <i>et al.</i> , "Soluble Transforming Growth Factor- β Type II Receptor Inhibits Negative Remodeling, Fibroblast Transdifferentiation, and Intimal Lesion Formation But Not Endothelial Growth," <i>Circ. Res.</i> 84:1212-1222, 1999	
		TERABE <i>et al.</i> , "NKT Cell-Mediated Repression of Tumor Immunosurveillance by IL-13 and the IL-4R-STAT6 Pathway," <i>Nat Immunol</i> 1(6):515-520, 2000	
		TSANG <i>et al.</i> , "Characterization of Recombinant Soluble Human Transforming Growth Factor- β Receptor Type II (rhTGF- β sRII)," <i>Cytokine</i> 7(5):389-397, 1995	
		TSUSHIMA <i>et al.</i> , "Circulating Transforming Growth Factor β_1 as a Predictor of Liver Metastasis after Resection in Colorectal Cancer," <i>Clin. Cancer Res.</i> 7:1258-1262, 2001	
		TURCO <i>et al.</i> , "Overexpression of Transforming Growth Factor 140969-Type II Receptor Reduces Tumorigenicity and Metastatic Potential of K-ras-Transformed Thyroid Cells," <i>Int. J. Cancer</i> 80:85-91, 1999	
		UENO <i>et al.</i> , "A Soluble Transforming Growth Factor β Receptor Expressed in Muscle Prevents Liver Fibrogenesis and Dysfunction in Rats," <i>Human Gene Ther.</i> 11:33-42, 2000	
		WANG <i>et al.</i> , "Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters," <i>Thorax</i> 54:805-812, 1999	
		WON <i>et al.</i> , "Tumorigenicity of Mouse Thymoma is Suppressed by Soluble Type II Transforming Growth Factor β Receptor Therapy," <i>Cancer Res.</i> 59:1273-1277, 1999	
		YANG <i>et al.</i> , "Lifetime Exposure to a Soluble TGF- β Antagonist Protects Mice Against Metastasis without Adverse Side Effects," <i>J. Clin. Invest.</i> 109(12):1607-1615, 2002	
		YIN <i>et al.</i> , "TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development," <i>J. Clin. Invest.</i> 103(2):197-206, 1999	
/SJH/		ZHENG <i>et al.</i> , "Recombinant Soluble Transforming Growth Factor β Type II Receptor Ameliorates Radiation Enteropathy in Mice," <i>Gastroenterol.</i> 119:1286-1296, 2000	
/SJH/		R&D Systems, Recombinant Human TGF- β sRII/Fc Chimera, 2000 (product information sheet, catalog No. 341-BR)	
/SJH/		R&D Systems, Recombinant Mouse TGF- β RII/Fc Chimera, 2000 (product information sheet, catalog No. 532-R2)	

EXAMINER SIGNATURE:	/Sheela J. Huff/	DATE CONSIDERED:	05/31/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			